Rutgers University Cell and DNA Repository Adopts Cryostor™ as Standard Biopreservation Media
News Apr 14, 2009
BioLife Solutions, Inc. has announced that the Rutgers University Cell and DNA Repository (RUCDR), the world’s largest university-based biologics repository, has adopted the Company’s CryoStor as the exclusive cryopreservation media for its transformed lymphocyte cell lines (LCL), which are used throughout the world by researchers working to find genetic causes of common, complex diseases such as alcohol/addiction, diabetes, autism, and numerous mental disorders.
Douglas A. Fugman, Ph.D., Managing Director of RUCDR, explained the decision to transition from an in-house formulated media containing culture media and fetal bovine serum to CryoStor by stating, “We continually strive to optimize our cell processing protocols to improve the quality of the cell lines we make available to researchers around the world. Our technical evaluation clearly indicated that CryoStor offered advantages in post-preservation cell recovery and we view pre-formulated, serum and protein free CryoStor as the best-in-class biopreservation media for cell banking applications.”
Mike Rice, BioLife’s chairman and CEO, noted, “We view this product adoption by RUCDR as further validation that our initiative to raise the quality and regulatory bar for biopreservation media products is being recognized and valued in our strategic markets. Dr. Fugman’s operations team processes over 36,000 cell lines annually and this represents significant volume demand for CryoStor. We expect to begin fulfilling orders in a custom package to support RUCDR within 60 days, following final validation of our internal manufacturing facility in Bothell.”
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.